Radioligand therapy (RLT)

Radioligand therapy

• This approach for precision delivery of radiation aims to destroy target cancer cells while limiting impact on healthy cells.
• Protein-ligands are envisioned to largely increase the accessible target space for RLT when compared to standard small molecule ligands.

Next-generation RLTs

• Athebody® DARPins are stability engineered to withstand the harsh radiolabeling conditions.
• The high specify and affinity of Athebody® DARPins together with their ease to generate multi-specific protein-ligands unlock novel therapies by increasing the accessible target space.
• The pharmacokinetics of Athebody® DARPins can readily be optimized to ideally balance tumor, kidney and bone marrow uptake which is fundamental for the clinical success of radioligands.